3 research outputs found

    Prospective Cases of New Onset Myocarditis/Pericarditis or cTnT Elevation Following Immunization with Either Smallpox or Trivalent Influenza Vaccine.

    No full text
    <p>*<b>Healthy 2002</b>: DoD Defense Medical Surveillance System pre-SPX MP incidence data.<sup>3</sup></p><p><sup>ā€”</sup><b>Prospective clinical myocarditis/pericarditis</b> cases included 4 Caucasian male cases of probable myocarditis (new onset cardiac symptoms (chest pain, dyspnea on exertion and/or at rest, palpitations) and cTnT elevations ā‰„0.02 ng/ml with the pre-vaccine level <0.01 ng/ml). The 5<sup>th</sup> case (female) was acute suspect pericarditis presenting with characteristic chest pain and no cTnT elevations or ECG changes. There were no cases in the TIV prospective study cohort.</p><p><sup>Ā§</sup><b>Comparison of Prospective Smallpox Vaccine Cohort with published historic retrospective epidemiologic estimate of myocarditis/pericarditis disease incidence in comparable population pre-SPX vaccine</b>: P<0.001.</p><p><sup>Ē</sup>Subclinical myocarditis is defined by increases in cTnT (above pre-immunization levels) without classic new onset cardiac symptoms. The comparison cohort does not reflect a dynamic change but a single level in time in healthy population subsequently followed for mortality relative risk. <b>Possible subclinical pericarditis</b>: There were no cases of possible subclinical pericarditis identified through the blinded ECG series review process.</p><p>Prospective Cases of New Onset Myocarditis/Pericarditis or cTnT Elevation Following Immunization with Either Smallpox or Trivalent Influenza Vaccine.</p
    corecore